Covid-19: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
oke 👌 |
Rescuing 0 sources and tagging 2 as dead.) #IABot (v2.0.8 |
||
Baris 123:
Untuk meredakan gejala demam, beberapa profesional medis merekomendasikan [[parasetamol]] (asetaminofen) dibandingkan [[ibuprofen]] untuk penggunaan lini pertama.<ref>{{Cite journal|last=Day|first=Michael|date=2020-03-17|title=Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists|url=http://www.bmj.com/lookup/doi/10.1136/bmj.m1086|journal=BMJ|language=en|pages=m1086|doi=10.1136/bmj.m1086|issn=1756-1833}}</ref><ref>{{Cite web|url=https://www.nhs.uk/conditions/coronavirus-covid-19/what-to-do-if-you-or-someone-you-live-with-has-coronavirus-symptoms/|title=What to do if you or someone you live with has symptoms of coronavirus|last=|first=|date=2020-04-22|website=National Health Service (United Kingdom)|language=en|access-date=2020-05-06}}</ref><ref>{{Cite web|url=https://www.npr.org/sections/health-shots/2020/03/18/818026613/advice-from-france-to-avoid-ibuprofen-for-covid-19-leaves-experts-baffled|title=Concerned About Taking Ibuprofen For Coronavirus Symptoms? Here's What Experts Say|website=NPR.org|language=en|access-date=2020-05-06}}</ref> WHO dan NIH tidak menentang penggunaan [[obat antiinflamasi nonsteroid]] (NSAID) seperti ibuprofen untuk meredakan gejala,<ref name=":5" /><ref>{{Cite web|url=https://www.sciencealert.com/who-recommends-to-avoid-taking-ibuprofen-for-covid-19-symptoms|title=Updated: WHO Now Doesn't Recommend Avoiding Ibuprofen For COVID-19 Symptoms|last=AFP|first=|date=19 Maret 2020|website=ScienceAlert|language=en-gb|access-date=2020-05-06}}</ref> sedangkan FDA menyatakan saat ini tidak ada bukti bahwa NSAID memperburuk gejala COVID-19.<ref>{{Cite journal|last=Research|first=Center for Drug Evaluation and|date=2020-03-19|title=FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19|url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19|journal=FDA|language=en}}</ref>
Meskipun muncul kekhawatiran secara teoritis tentang [[inhibitor ACE]] dan [[pengeblok reseptor angiotensin]], pada 19 Maret 2020, kekhawatiran ini tidak cukup untuk membenarkan penghentian obat-obatan ini.<ref name=":5" /><ref>{{Cite web|url=https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician|title=Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician|website=American Heart Association|language=en-us|access-date=2020-05-06}}</ref><ref>{{Cite web|url=https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang,%20https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang|title=Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers|website=www.escardio.org|access-date=2020-05-06}}{{Pranala mati|date=Mei 2021 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> Penelitian pada 22 April menemukan bahwa orang-orang dengan COVID-19 dan hipertensi memiliki angka kematian yang lebih rendah karena penggunaan obat-obatan ini.<ref>{{Cite web|url=https://www.pharmacytimes.com/news/new-evidence-concerning-safety-of-ace-inhibitors-arbs-in-covid-19|title=New Evidence Concerning Safety of ACE Inhibitors, ARBs in COVID-19|website=Pharmacy Times|access-date=2020-05-06}}</ref>
[[Steroid]], seperti [[metilprednisolon]], tidak dianjurkan kecuali penyakitnya dipersulit oleh [[sindrom gangguan pernapasan akut]] (ARDS).<ref>{{Cite journal|last=Vetter|first=Pauline|last2=Eckerle|first2=Isabella|last3=Kaiser|first3=Laurent|date=2020-02-19|title=Covid-19: a puzzle with many missing pieces|url=http://www.bmj.com/lookup/doi/10.1136/bmj.m627|journal=BMJ|language=en|pages=m627|doi=10.1136/bmj.m627|issn=1756-1833}}</ref><ref>{{Cite web|url=https://www.ebmedicine.net/topics/infectious-disease/COVID-19,%20https://www.ebmedicine.net/topics/infectious-disease/COVID-19|title=Novel Coronavirus—COVID-19: What Emergency Clinicians Need to Know|last=|first=|date=2020-03-23|website=EBMEDICINE|language=en|access-date=2020-05-06}}{{Pranala mati|date=Mei 2021 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>
[[Perhimpunan Imunologi Klinis dan Alergi Australasia]] merekomendasikan bahwa [[tosilizumab]] perlu dipertimbangkan sebagai pilihan pengobatan bagi mereka yang mengalami ARDS yang terkait dengan COVID-19. Rekomendasi ini dilakukan karena obat ini diketahui bermanfaat dalam [[badai sitokin]] yang disebabkan oleh [[Sel T reseptor antigen kimerik|pengobatan kanker tertentu]], dan bahwa badai sitokin mungkin merupakan kontributor signifikan terhadap kematian pada COVID-19 yang berat.<ref>{{Cite web|url=https://allergy.org.au/hp/papers/specific-treatments-for-covid-19|title=ASCIA Position Statement: Specific Treatments for COVID-19|last=Grainger|first=Suzanne|website=Australasian Society of Clinical Immunology and Allergy (ASCIA)|language=en-gb|access-date=2020-05-06|archive-date=2020-06-16|archive-url=https://web.archive.org/web/20200616150611/https://allergy.org.au/hp/papers/specific-treatments-for-covid-19|dead-url=yes}}</ref>
| |||